Indian Healthcare Observer

Drugs and Cosmetics (Amendment) Bill gets Presidents' assent

Even as the pharma industry is making concerted efforts to rectify the Drugs and Cosmetics (Amendment) Bill to incorporate certain provisions to safeguard the interests of genuine manufacturers, the controversial Bill has received the assent of the President.

Global Healthcare's Medicity selects SAP to support clinical services

Global Healthcare Pvt Ltd (Medicity), a state-of-the-art medical centre has now installed SAP ERP ECC 6.0 application as the standard technology platform to streamline its operations.

Shilpa Medicare bags the Certificate of Suitability of Monographs from EDQM

Shilpa Medicare Ltd has bagged the Certificate of Suitability of Monographs from the European Directorate for the Quality of Medicines (EDQM) for the Active Pharmaceutical Ingredient (API) Gemcitabine HCI EP.

Soaring rupee, global recession affect Indian analytical instruments market

The analytical instruments market in India is facing a major downfall in the backdrop of the recent rupee appreciation and the global financial melt down, which will cut down the rapid growth rate of more than 15 per cent recorded in last few years to nearly 10 per cent in the current financial year.

India's health insurance sector to grow by 38%

Though confronted with predicaments such as lack of transparency in data collection and common standards in healthcare services, the budding health insurance sector in India is expected to grow at 38 per cent to reach Rs 50,000 crore in the next ten years.

Centre makes use of auto disable syringes mandatory in govt hospitals

Close on the heels of launching a nationwide intensive public awareness campaign on unsafe injections, Marc Koska, founder of the SafePoint Trust UK in pursuit of its mandate in implementing use of only auto disable syringes, has managed to convince the Government of India which has now made it mandatory to use only auto disable syringes from April 2009.

J&J receives Israeli nod to acquire Omrix

Johnson & Johnson (J&J) announced that the Israeli general director of the Antitrust Authority has approved Johnson & Johnson's proposed acquisition of Omrix Biopharmaceuticals, Inc, under the Restrictive Trade Practices Law 5748-1988 of Israel.

GE capitalizes on RSNA platform to showcase its 'Early Health' model

GE healthcare, a unit of General Electric Company is focusing on increasing its market presence with its range of products under its 'Early Health' initiatives.

DCC sets up sub committee to weed out artemisinin from Indian market

Artemisinin, the drug used as monotherapy to treat multi-drug resistant strains of falciparum malaria, will no longer be in the Indian market after some time as a decision to discontinue its use has already been taken.

GLP Rules notified, pharma cos directed to implement by Nov, 2010

Ministry of health has notified the Schedule L-I of Rules 74, 78 and 150 E under Drugs and Cosmetics Third Amendment Rules 2008 giving the pharmaceutical industry time till November 1, 2010 for compliance of Good Laboratory Practices.